Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, Netherlands.
Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre, University of Amsterdam.
BMJ. 2015 Jan 9;350:g7771. doi: 10.1136/bmj.g7771.
To compare the effectiveness of in vitro fertilisation with single embryo transfer or in vitro fertilisation in a modified natural cycle with that of intrauterine insemination with controlled ovarian hyperstimulation in terms of a healthy child.
Multicentre, open label, three arm, parallel group, randomised controlled non-inferiority trial.
17 centres in the Netherlands.
Couples seeking fertility treatment after at least 12 months of unprotected intercourse, with the female partner aged between 18 and 38 years, an unfavourable prognosis for natural conception, and a diagnosis of unexplained or mild male subfertility.
Three cycles of in vitro fertilisation with single embryo transfer (plus subsequent cryocycles), six cycles of in vitro fertilisation in a modified natural cycle, or six cycles of intrauterine insemination with ovarian hyperstimulation within 12 months after randomisation.
The primary outcome was birth of a healthy child resulting from a singleton pregnancy conceived within 12 months after randomisation. Secondary outcomes were live birth, clinical pregnancy, ongoing pregnancy, multiple pregnancy, time to pregnancy, complications of pregnancy, and neonatal morbidity and mortality
602 couples were randomly assigned between January 2009 and February 2012; 201 were allocated to in vitro fertilisation with single embryo transfer, 194 to in vitro fertilisation in a modified natural cycle, and 207 to intrauterine insemination with controlled ovarian hyperstimulation. Birth of a healthy child occurred in 104 (52%) couples in the in vitro fertilisation with single embryo transfer group, 83 (43%) in the in vitro fertilisation in a modified natural cycle group, and 97 (47%) in the intrauterine insemination with controlled ovarian hyperstimulation group. This corresponds to a risk, relative to intrauterine insemination with ovarian hyperstimulation, of 1.10 (95% confidence interval 0.91 to 1.34) for in vitro fertilisation with single embryo transfer and 0.91 (0.73 to 1.14) for in vitro fertilisation in a modified natural cycle. These 95% confidence intervals do not extend below the predefined threshold of 0.69 for inferiority. Multiple pregnancy rates per ongoing pregnancy were 6% (7/121) after in vitro fertilisation with single embryo transfer, 5% (5/102) after in vitro fertilisation in a modified natural cycle, and 7% (8/119) after intrauterine insemination with ovarian hyperstimulation (one sided P=0.52 for in vitro fertilisation with single embryo transfer compared with intrauterine insemination with ovarian hyperstimulation; one sided P=0.33 for in vitro fertilisation in a modified natural cycle compared with intrauterine insemination with controlled ovarian hyperstimulation).
In vitro fertilisation with single embryo transfer and in vitro fertilisation in a modified natural cycle were non-inferior to intrauterine insemination with controlled ovarian hyperstimulation in terms of the birth of a healthy child and showed comparable, low multiple pregnancy rates.Trial registration Current Controlled Trials ISRCTN52843371; Nederlands Trial Register NTR939.
比较体外受精-胚胎移植或改良自然周期体外受精与控制性卵巢超排卵宫腔内人工授精在活产健康婴儿方面的有效性。
多中心、开放标签、三臂、平行组、随机对照非劣效性试验。
荷兰 17 个中心。
寻求生育治疗的夫妇,至少有 12 个月的无保护性行为,女性年龄在 18 至 38 岁之间,自然受孕预后不良,诊断为不明原因或轻度男性不育。
随机分组后 12 个月内,分别进行 3 个周期的体外受精-胚胎移植(加后续冷冻周期)、6 个周期的改良自然周期体外受精或 6 个周期的控制性卵巢超排卵宫腔内人工授精。
主要结局为随机分组后 12 个月内单胎妊娠活产健康婴儿。次要结局为活产、临床妊娠、持续妊娠、多胎妊娠、妊娠时间、妊娠并发症和新生儿发病率和死亡率。
2009 年 1 月至 2012 年 2 月,602 对夫妇随机分配,201 对接受体外受精-胚胎移植,194 对接受改良自然周期体外受精,207 对接受控制性卵巢超排卵宫腔内人工授精。体外受精-胚胎移植组 104 对(52%)、改良自然周期体外受精组 83 对(43%)和控制性卵巢超排卵宫腔内人工授精组 97 对(47%)妊娠活产健康婴儿。这对应于与控制性卵巢超排卵宫腔内人工授精相比,体外受精-胚胎移植的风险为 1.10(95%置信区间 0.91 至 1.34),改良自然周期体外受精的风险为 0.91(0.73 至 1.14)。这些 95%置信区间未低于劣效性的预设阈值 0.69。体外受精-胚胎移植后持续妊娠的多胎妊娠率为 6%(7/121),改良自然周期体外受精后为 5%(5/102),控制性卵巢超排卵宫腔内人工授精后为 7%(8/119)(一侧 P=0.52 比较体外受精-胚胎移植与控制性卵巢超排卵宫腔内人工授精;一侧 P=0.33 比较改良自然周期体外受精与控制性卵巢超排卵宫腔内人工授精)。
体外受精-胚胎移植和改良自然周期体外受精在活产健康婴儿方面不劣于控制性卵巢超排卵宫腔内人工授精,且显示出相似的低多胎妊娠率。
当前对照试验 ISRCTN52843371;荷兰试验注册 NTR939。